Single Nucleotide Polymorphisms in the Tumor Necrosis Factor-Alpha Gene Promoter Region Alter the Risk of Psoriasis Vulgaris and Psoriatic Arthritis: A Meta-Analysis
Background It has been confirmed that tumor necrosis factor-alpha (TNFα), a macrophage-derived pro-inflammatory cytokine, plays an important role in the pathogenesis of psoriasis vulgaris and psoriatic arthritis (PsV&PsA). In contrast, the reported association of TNFα gene promoter region single nucleotide polymorphisms (SNPs) and PsV&PsA has remained controversial. Accordingly, we performed a meta-analysis to provide new evidence that SNPs in the TNFα gene promoter region alter not only the risk of psoriasis vulgaris (PsV) or psoriatic arthritis (PsA) but also of PsV&PsA. Methods Interrelated literature dated to October 2012 was acquired from the PubMed, ScienceDirect, and SpringerLink databases. The number of the genotypes and/or alleles for the TNFα promoter in the PsV and PsA and control subjects was obtained. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to calculate the risk of PsV and/or PsA with TNFα promoter SNPs. Results A total of 26 papers of 2159 for PsV (2129 normal controls) and 2360 for PsA (2997 normal controls) were included in our meta-analysis. The results showed that the variant genotype and allele of TNFα -308A/G was protective in pooled groups of patients with PsV&PsA (OR = 0.682, 0.750; 95% CI, 0.596-0.779, 0.653-0.861). However, the variant genotypes and alleles of TNFα -238A/G and -857T/C had an increased risk of PsV&PsA (OR = 2.493, 2.228, 1.536, 1.486, 95% CI, 1.777-3.498, 1.628-3.049, 1.336-1.767, 1.309-1.685). Moreover, the meta-analysis revealed a significant association between TNFα -238A/G and -857T/C polymorphism and PsA susceptibility (OR = 2.242, 2.052, 1.419, 1.465; 95% CI, 1.710-2.941, 1.614-2.610, 1.214-1.658, 1.277-1.681). In contrast, the variant genotypes and alleles of TNFα -308A/G proved to be protective against PsV (OR = 0.574, 0.650, 95% CI, 0.478-0.690, 0.556-0.759), whereas TNFα -238A/G was found to have a risk association (OR = 2.636, 2.223, 95% CI, 1.523-4.561, 1.317-3.751). Conclusions SNPs in the TNFα gene promoter region alter the risk of PsV and/or PsA.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2012) Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. J Invest Dermatol.
[3]
Scarpa R, Oriente P, Pucino A, Torella M, Vignone L, et al. (1984) Psoriatic arthritis in psoriatic patients. Br J Rheumatol 23: 246–250.
[4]
Scarpa R, Ayala F, Caporaso N, Olivieri I (2006) Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 33: 210–212.
[5]
Mease P (2004) TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 63: 755–758.
[6]
Kane D, FitzGerald O (2004) Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective. Curr Rheumatol Rep 6: 292–298.
[7]
Cui G, Wang H, Li R, Zhang L, Li Z, et al. (2012) Polymorphism of tumor necrosis factor alpha (TNF-alpha) gene promoter, circulating TNF-alpha level, and cardiovascular risk factor for ischemic stroke. J Neuroinflammation 9: 235.
[8]
Kaluza W, Reuss E, Grossmann S, Hug R, Schopf RE, et al. (2000) Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol 114: 1180–1183.
[9]
Lee YH, Ji JD, Song GG (2007) Tumor necrosis factor-alpha promoter -308 A/G polymorphism and rheumatoid arthritis susceptibility: a metaanalysis. J Rheumatol 34: 43–49.
[10]
Li B, Wang P, Li H (2010) The association between TNF-alpha promoter polymorphisms and ankylosing spondylitis: a meta-analysis. Clin Rheumatol 29: 983–990.
[11]
Li C, Wang G, Gao Y, Liu L, Gao T (2007) TNF-alpha gene promoter -238G>A and -308G>A polymorphisms alter risk of psoriasis vulgaris: a meta-analysis. J Invest Dermatol 127: 1886–1892.
[12]
Xie C, Liu XF, Yang MS (2012) A meta-analysis on the association between three promoter variants of TNF-alpha and Crohn's disease. Mol Biol Rep 39: 1575–1583.
[13]
Rahman P, Siannis F, Butt C, Farewell V, Peddle L, et al. (2006) TNFalpha polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis 65: 919–923.
[14]
Gallo E, Cabaleiro T, Roman M, Abad-Santos F, Dauden E (2012) [Study of genetic polymorphisms in the tumor necrosis factor alpha promoter region in Spanish patients with psoriasis]. Actas Dermosifiliogr 103: 301–307.
[15]
Nedoszytko B, Szczerkowska-Dobosz A, Zablotna M, Glen J, Rebala K, et al. (2007) Associations of promoter region polymorphisms in the tumour necrosis factor-alpha gene and early-onset psoriasis vulgaris in a northern Polish population. Br J Dermatol 157: 165–167.
[16]
Ruiz DG, Azevedo MN, Santos OL (2012) Psoriatic arthritis: a clinical entity distinct from psoriasis? Rev Bras Reumatol 52: 630–638.
[17]
Giardina E, Huffmeier U, Ravindran J, Behrens F, Lepre T, et al. (2011) Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locus. Arthritis Rheum 63: 3801–3806.
[18]
Magalhaes RF, Biral AC, Pancoto JA, Donadi EA, Mendes CJ, et al. (2010) Human leukocyte antigen (HLA) and single nucleotide polymorphisms (SNPs) tumor necrosis factor (TNF)-alpha -238 and -308 as genetic markers of susceptibility to psoriasis and severity of the disease in a long-term follow-up Brazilian study. Int J Dermatol 49: 1133–1140.
[19]
Settin A, Hassan H, El-Baz R, Hassan T (2009) Association of cytokine gene polymorphisms with psoriasis in cases from the Nile Delta of Egypt. Acta Dermatovenerol Alp Panonica Adriat 18: 105–112.
[20]
Popa OM, Bojinca M, Bojinca V, Dutescu MI, Meirosu M, et al. (2011) A pilot study of the association of tumor necrosis factor alpha polymorphisms with psoriatic arthritis in the romanian population. Int J Mol Sci 12: 5052–5059.
[21]
Reich K, Huffmeier U, Konig IR, Lascorz J, Lohmann J, et al. (2007) TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum 56: 2056–2064.
[22]
Wells GA, Shea B, O'Connell D, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. ottawa hospital research institute website. Available: http://www.ohri.ca/programs/clinical_epi？demiology/oxford.asp. Accessed 2013 Apr 22.
[23]
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.
[24]
Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21: 1559–1573.
[25]
Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
[26]
Balding J, Kane D, Livingstone W, Mynett-Johnson L, Bresnihan B, et al. (2003) Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 48: 1408–1413.
[27]
Gonzalez S, Martinez-Borra J, Lopez-Vazquez A, Garcia-Fernandez S, Torre-Alonso JC, et al. (2002) MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis. J Rheumatol 29: 973–978.
[28]
Al-Heresh AM, Proctor J, Jones SM, Dixey J, Cox B, et al. (2002) Tumour necrosis factor-alpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis. Rheumatology (Oxford) 41: 525–530.
[29]
Hohler T, Grossmann S, Stradmann-Bellinghausen B, Kaluza W, Reuss E, et al. (2002) Differential association of polymorphisms in the TNFalpha region with psoriatic arthritis but not psoriasis. Ann Rheum Dis 61: 213–218.
[30]
Gonzalez S, Brautbar C, Martinez-Borra J, Lopez-Vazquez A, Segal R, et al. (2001) Polymorphism in MICA rather than HLA-B/C genes is associated with psoriatic arthritis in the Jewish population. Hum Immunol 62: 632–638.
[31]
Hamamoto Y, Tateno H, Ishida T, Muto M (2000) Lack of association between promoter polymorphism of the tumor necrosis factor-alpha gene and psoriatic arthritis in Japanese patients. J Invest Dermatol 115: 1162–1164.
[32]
Hohler T, Kruger A, Schneider PM, Schopf RE, Knop J, et al. (1997) A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 109: 562–565.
[33]
Baran W, Szepietowski JC, Mazur G, Baran E (2006) A - 308 promoter polymorphism of tumor necrosis factor alpha gene does not associate with the susceptibility to psoriasis vulgaris. No difference either between psoriasis type I and type II patients. Acta Dermatovenerol Alp Panonica Adriat 15: 113–118.
[34]
Mossner R, Kingo K, Kleensang A, Kruger U, Konig IR, et al. (2005) Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol 124: 282–284.
[35]
Long F, Sun C, Deng D, Zhou X, Li XP, et al. (2004) TNF-238A is associated with juvenile onset psoriasis in patients of Han population in Southwest China. J Dermatol Sci 36: 109–111.
[36]
Tsunemi Y, Nishibu A, Saeki H, Oyama N, Nakamura K, et al. (2003) Lack of association between the promoter polymorphisms at positions -308 and -238 of the tumor necrosis factor alpha gene and psoriasis vulgaris in Japanese patients. Dermatology 207: 371–374.
[37]
Kim TG, Pyo CW, Hur SS, Kim YK, Hwang HY, et al. (2003) Polymorphisms of tumor necrosis factor (TNF) alpha and beta genes in Korean patients with psoriasis. Arch Dermatol Res 295: 8–13.
[38]
Chang YT, Tsai SF, Lee DD, Shiao YM, Huang CY, et al. (2003) A study of candidate genes for psoriasis near HLA-C in Chinese patients with psoriasis. Br J Dermatol 148: 418–423.
[39]
Reich K, Mossner R, Konig IR, Westphal G, Ziegler A, et al. (2002) Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol 118: 155–163.
[40]
Craven NM, Jackson CW, Kirby B, Perrey C, Pravica V, et al. (2001) Cytokine gene polymorphisms in psoriasis. Br J Dermatol 144: 849–853.
[41]
Reich K, Westphal G, Schulz T, Muller M, Zipprich S, et al. (1999) Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. J Invest Dermatol 113: 214–220.
[42]
Jacob N, Ruschendorf F, Schmitt-Egenolf M, Hennies HC, Friedl G, et al. (1999) Promoter polymorphism at -238 of the tumor necrosis factor alpha gene is not associated with early onset psoriasis when tested by the transmission disequilibrium test. J Invest Dermatol 112: 514–516.
[43]
Vasilopoulos Y, Manolika M, Zafiriou E, Sarafidou T, Bagiatis V, et al. (2012) Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther 16: 29–34.
[44]
Mekinian A, Tamouza R, Pavy S, Gestermann N, Ittah M, et al. (2011) Functional study of TNF-alpha promoter polymorphisms: literature review and meta-analysis. Eur Cytokine Netw 22: 88–102.
[45]
Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM (2009) Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum 60: 1815–1824.
[46]
Lv K, Chen R, Cai Q, Fang M, Sun S (2006) Effects of a single nucleotide polymorphism on the expression of human tumor necrosis factor-alpha. Scand J Immunol 64: 164–169.
[47]
Butter F, Davison L, Viturawong T, Scheibe M, Vermeulen M, et al. (2012) Proteome-wide analysis of disease-associated SNPs that show allele-specific transcription factor binding. PLoS Genet 8: e1002982.
